Citigroup initiated coverage on BioAge Labs with a new price target
$BIOA
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $45.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
| 12/9/2024 | $45.00 → $7.00 | Buy → Neutral | Citigroup |
| 10/21/2024 | $45.00 | Buy | Citigroup |
| 10/21/2024 | $42.00 | Buy | Jefferies |
| 10/21/2024 | $40.00 | Overweight | Morgan Stanley |
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a multi-year research collaboration with Novartis. The collaboratio
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today an
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com, and will be archived for 30 days following the presentation. About BioAge Labs, Inc.BioAge is a
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously
Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously
Citigroup downgraded BioAge Labs from Buy to Neutral and set a new price target of $7.00 from $45.00 previously
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
8-K - BioAge Labs, Inc. (0001709941) (Filer)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)